Abbvie statement ovarian cancer
Montreal, May 14, 2026 AbbVie Canada was informed by the pan-Canadian Pharmaceutical Alliance (pCPA) that they have closed negotiations for ELAHERE (mirvetuximab soravtansine for injection) without the completion of an agreement. AbbVie received the information with tremendous disappointment considering the important need for innovative treatment options for women living with platinum resistant ovarian cancer who are vulnerable and dependent on the public healthcare system. At AbbVie, our mission is to discover and deliver innovative medicines and technologies that solve the world’s toughest health challenges. As we assess next steps, our unwavering commitment remains to bring the best science to patients.
Media Inquiries:
Natacha Raphael Head, Corporate Affairs & Patient Engagement, Canada
AbbVie
[email protected]
At AbbVie in Canada, we acknowledge that we live and work on the traditional territories of many First Nations, Inuit and Métis Peoples. We would like to show respect to those Peoples who are the original and ongoing stewards of this land we call our home. We are grateful to collaborate on these traditional lands and humbled by the work that we do to enhance people’s lives in our communities.
Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.
Copyright® 2026 AbbVie Corporation. Canada..